De novo Biotherapeutics
Latest round
- Series A
Last raised
- Nov 2022
Total raised
- $7.1M
Investors
- 4
About De novo Biotherapeutics
Based in Seoul, South Korea, and founded in 2021, D De novo Biotherapeutics, Inc.a. De novo Biotherapeutics is a biotechnology firm that focuses on developing mRNA (messenger ribonucleic acid) encoded and NK (natural killer) cell-engaging bi- or multi-specific antibodies for the treatment, diagnosis, and prevention of cancer. As of November 2022, Changhoon Choi is the CEO of the company. The company develops multi-specific antibodies through mRNA technology to harness the anti-tumor activity of patients’ NK cells. The product pipeline of De novo Biotherapeutics includes DNB -101, DNB -102, and DNB -103, targeting cancer diseases.
Who invested in De novo Biotherapeutics
4 investors across 2 rounds
See all investors in De novo Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about De novo Biotherapeutics
Who invested in De novo Biotherapeutics?
De novo Biotherapeutics has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has De novo Biotherapeutics raised?
De novo Biotherapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did De novo Biotherapeutics last raise money?
De novo Biotherapeutics's most recent round on record is a Series A, in Nov 2022.
What does De novo Biotherapeutics do?
Based in Seoul, South Korea, and founded in 2021, D De novo Biotherapeutics, Inc.
Where is De novo Biotherapeutics headquartered?
De novo Biotherapeutics is headquartered in Seoul, South Korea.
Which VCs invest in companies like De novo Biotherapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at De novo Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like De novo Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.